| Written | 2006-03 | JF Fu, LY Shih |
| Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 199 Tung-Hwa North Road, Taipei 105, Taiwan |
| Identity |
| ICD-Topo | C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS |
| ICD-Morpho | 9807/3 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged |
| ICD-Morpho | 9811/3 B lymphoblastic leukaemia/lymphoma, NOS |
| ICD-Morpho | 9813/3 B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged |
| Atlas_Id | 1415 |
| Clinics and Pathology |
| Disease | pro-B acute lymphoblastic leukemia (L2) |
| Epidemiology | One case described (42 yrs); male |
| Clinics | The patient presented with fever and chills for 10 days. He had multiple 0.5 to 1.0 cm lymph nodes on bilateral necks, axillary and inguinal areas. He had no hepatosplenomegaly. His initial blood counts were HB 10.3 gm/dL, WBC 579.0 x 109/L with 97% blasts, and platelet 37.0 x 109/L. |
| Cytology | Bone marrow smear showed 99% blasts (FAB L2), which were negative for myeloperoxidase and exhibited diffuse fine granular patterns for PAS and acid phosphatase stains. Immunophenotypic analysis showed that the blasts were positive for CD19, CD33, CD34, HLA-DR and cyCD79; and negative for CD10, CD7, CD2, CD13, and cyMPO. |
| Treatment | The patient refused chemotherapy |
| Cytogenetics |
| Cytogenetics Morphological | Cytogenetic analysis was not performed. |
| Genes involved and Proteins |
| Gene Name | KMT2A (myeloid/lymphoid or mixed lineage leukemia) |
| Location | 11q23.3 |
| Protein | 431 KDa; contains two DNA binding motifs (a AT hook, and Zinc fingers), a DNA methyltransferase motif, and a SET [Su(var)3-9, enhancer of Zeste, and trithorax] doamin |
| Gene Name | MAPRE1 (Microtubule-associated protein, RP/EB family, member 1) |
| Location | 20q11.21 |
| Protein | MAPRE1 encoding EB1 which contains a microtubule-binding domain, a dynactin-binding domain (DBD), and an APC-binding domain that is overlapped to DBD; localized at cytoplasmic microtubule tips, centrosomes, and spindle microtubules, and interacts with APC or dynein/dynactin complex to regulate microtubule dynamics, cell polarity, and chromosomal stability |
| Result of the chromosomal anomaly |
| Partial nucleotide and deduced amino acid sequence of the break junctions of MLL-MAPRE1 and MAPRE1-MLL fusion transcripts. Vertical lines indicate break junctions. | |
 | |
| Description | 5' MLL-3' MAPRE1, with fusion of MLL exon 6 to MAPRE1 exon 5; the reciprocal in-frame MAPRE1-MLL is also transcribed |
| Detection | cDNA panhandle PCR |
 | |
| Schematic representation of MLL-EB1 and EB1-MLL fusion proteins. AT-H, AT hooks; MT, DNA methyltansferase motif; Zn-F, zinc finger domain; SET, [Su(var]3-9, enhancer of zeste, and trithorax] domain; En, microtubule-binding domain; ABD, APC-binding domain; numbers indicate amino acids of each protein. | |
| Description | NH2-AT hook and DNA methyltransferase motif from MLL fused to APC-binding domain of EB1 |
| To be noted |
| Additional cases are needed to delineate the epidemiology of this rare entity: you are welcome to submit a paper to our new Case Report section. |
| Bibliography |
| MLL is fused to EB1 (MAPRE1), which encodes a microtubule-associated protein, in a patient with acute lymphoblastic leukemia. |
| Fu JF, Hsu HC, Shih LY |
| Genes, chromosomes & cancer. 2005 ; 43 (2) : 206-210. |
| PMID 15751040 |
| Citation |
| This paper should be referenced as such : |
| Fu, JF ; Shih, LY |
| t(11;20)(q23;q11) |
| Atlas Genet Cytogenet Oncol Haematol. 2006;10(3):199-200. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Anomalies/t1120q23q11ID1415.html |
| Translocations implicated (Data extracted from papers in the Atlas) |
| t(11;20)(q23;q11) KMT2A/MAPRE1 | |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| All articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Wed Nov 13 22:14:45 CET 2019 |
For comments and suggestions or contributions, please contact us